Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

ClinicalTrials.gov ID: NCT01711528

Public ClinicalTrials.gov record NCT01711528. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Study identification

NCT ID
NCT01711528
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
41 participants

Conditions and interventions

Interventions

  • Bortezomib Drug
  • Dexamethasone Drug
  • Dinaciclib Drug
  • Laboratory Biomarker Analysis Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 18, 2012
Primary completion
Nov 21, 2016
Completion
Nov 21, 2016
Last update posted
May 10, 2018

2012 – 2016

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Mayo Clinic in Arizona Scottsdale Arizona 85259
Mayo Clinic Rochester Minnesota 55905
M D Anderson Cancer Center Houston Texas 77030
Virginia Commonwealth University/Massey Cancer Center Richmond Virginia 23298
University of Wisconsin Hospital and Clinics Madison Wisconsin 53792
Aspirus UW Cancer Center Wisconsin Rapids Wisconsin 54494

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01711528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 10, 2018 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01711528 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →